ERBB2 and gastroesophageal junction adenocarcinoma: Furthermore, trastuzumab (TZ, anti-HER-2 mAb) is used in the clinic for the treatment of HER-2 positive breast cancer patients [54] and gastroesophageal junction adenocarcinoma patients [55].